Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
▼
$18.00
$834.46MN/A11,851 shs39 shs
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$1.15
$1.16
$0.81
▼
$1.65
$14.18M0.8511,089 shs431 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
0.00%0.00%0.00%0.00%+32.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
▼
$18.00
$834.46MN/A11,851 shs39 shs
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$1.15
$1.16
$0.81
▼
$1.65
$14.18M0.8511,089 shs431 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
0.00%0.00%0.00%0.00%+32.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00
N/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$525.58M1.59N/AN/A$0.16 per share106.63
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$9.35M1.52N/AN/A$4.25 per share0.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
-$74.86MN/AN/AN/AN/A-15.31%N/A-4.38%N/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
257.04
2.39
1.61
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/A
3.61
3.61

Institutional Ownership

CompanyInstitutional Ownership
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
63.88%

Insider Ownership

CompanyInsider Ownership
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
3.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
42948.91 millionN/ANot Optionable
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
16012.33 million11.79 millionOptionable

Recent News About These Companies

HOOKIPA Pharma stock holds steady as investors await next clinical milestones
September 21, 2026  |  ad-hoc-news.deA
HOOKIPA Pharma
April 6, 2026  |  fool.comhttps://www.fool.com/quote/otc/hook/
HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
March 27, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/hookipa-pharma-announces-completion-of-sale-of-oncology-assets-to-neotrail-therapeutics-1035966320
Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral
March 21, 2026  |  fiercebiotech.comF
HOOKIPA Pharma Inc. Sells Immuno-Oncology Assets HB-200 and HB-700 to NeoTrail Therapeutics
February 3, 2026  |  quiverquant.comQ
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
February 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/03/3231081/0/en/hookipa-pharma-announces-sale-of-oncology-assets-to-neotrail-therapeutics.html
HOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead Sciences
October 31, 2025  |  quiverquant.comQ
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
October 31, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/31/3178274/0/en/hookipa-pharma-announces-completion-of-sale-of-hbv-and-hiv-assets-to-gilead.html
VALANX Biotech appoints Klaus Orlinger, PhD. as Chief Scientific Officer
October 30, 2025  |  cambridgenetwork.co.ukC
VALANX Biotech names Klaus Orlinger as chief scientific officer
October 30, 2025  |  thepharmaletter.comT
HOOKIPA Pharma Inc. (NASDAQ:HOOK) CFO Mary Theresa Coelho Sells 13,609 Shares
July 24, 2025  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-hook-insider-buying-and-selling-2025-07-24/
Hookipa, having sold off vaccines to Gilead, opts to wind down
July 21, 2025  |  fiercebiotech.comF
Serial dealmaker Cathal Friel: ‘It’s important not to hand easy money to the next generation’
July 18, 2025  |  irishtimes.comhttps://www.irishtimes.com/business/2025/07/18/serial-dealmaker-cathal-friel-its-not-money-that-motivates-me-i-get-much-more-fun-out-of-creating-something/
HOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead Sciences
July 18, 2025  |  quiverquant.comQ
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
July 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/18/3118174/0/en/hookipa-pharma-announces-intention-to-voluntarily-delist-and-deregister-its-common-stock.html
Hookipa Pharma Inc News (HOOK) - Investing.com
June 24, 2025  |  investing.comhttps://www.investing.com/equities/hookipa-pharma-inc-news/5
Adjuvant Nivolumab + CRT Improves Disease-Free Survival in Head and Neck Cancer
June 2, 2025  |  medscape.comM
Gilead (GILD) to Acquire HOOK for $10 million
May 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/gilead-gild-to-acquire-hook-for-10-million/ar-AA1FmazS
Gilead to buy certain Hookipa Pharma assets for up to $10M
May 22, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/gilead-to-buy-certain-hookipa-pharma-assets-for-up-to-10m/ar-AA1FhX34
Immuneering appoints Igor Matushansky as CMO
March 20, 2025  |  thepharmaletter.comT
ADVANZ PHARMA stock logo

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)
As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

HOOKIPA Pharma stock logo

HOOKIPA Pharma NASDAQ:HOOK

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas